Protection from the 2009 h1n1 pandemic influenza by an antibody from combinatorial survivor-based libraries

PLoS Pathogens

Volumn 6, Issue 7, 2010, Pages 1-7

  Kashyap, Arun K ^a   Steel, John ^b   Rubrum, Adam ^c   Estelles, Angeles ^a   Briante, Raffaella ^a   Ilyushina, Natalia A ^c   Xu, Li ^a   Swale, Ryann E ^a   Faynboym, Aleksandr M ^a   Foreman, Pamela K ^a   Michael Horowitz, M H ^a   Horowitz, Lawrence ^a   Webby, Richard ^c   Palese, Peter ^b   Lerner, Richard A ^d   Bhatt, Ramesh R ^a  

^a Sea Lane Biotechnologies ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY A06; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; POPULATION; PROPHYLAXIS; SEASONAL INFLUENZA; SURVIVOR; ANIMAL; CROSS REACTION; DISEASE MODEL; EPIDEMIC; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INFLUENZA; METHODOLOGY; ORTHOMYXOVIRUS INFECTION;

MURINAE; ORTHOMYXOVIRIDAE; SUIDAE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CROSS REACTIONS; DISEASE MODELS, ANIMAL; DISEASE OUTBREAKS; HUMANS; IMMUNOTHERAPY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MICE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVORS;

EID: 77957678820     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000990     Document Type: Article

References (21)

1. Cohen J, Enserink M (2009) Swine flu. After delays, WHO agrees: the 2009 pandemic has begun. Science 324: 1496-1497.
2. Zarocostas J (2009) World Health Organization declares A (H1N1) influenza pandemic. BMJ 338: b2425.
3. Air GM, Laver WG (1989) The neuraminidase of influenza virus. Proteins 6: 341-356.
4. Boni MF, Gog JR, Andreasen V, Christiansen FB (2004) Influenza drift and epidemic size: the race between generating and escaping immunity. Theor Popul Biol 65: 179-191.
5. Hilleman MR (2002) Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20: 3068-3087.
6. Park AW, Daly JM, Lewis NS, Smith DJ, Wood JL, et al. (2009) Quantifying the impact of immune escape on transmission dynamics of influenza. Science 326:726-728.
7. Casadevall A (2002) Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 8: 833-841.
8. Cheng LW, Stanker LH, Henderson TD, 2nd, Lou J, Marks JD (2009) Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 77: 4305-4313.
9. Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, et al. (1999) Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 18: 223-231.
10. Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47: 57-77.
11. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145: 599-609.
12. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105: 5986-5991.
13. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
14. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
15. Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog 6: e1000745.
16. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, et al. (2008) The influenza virus resource at the National Center for Biotechnology Information. J Virol 82: 596-601.
17. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
18. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
19. Poland GA, Jacobson RM, Ovsyannikova IG (2009) Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis 48: 1254-1256.
20. Lackenby A, Thompson CI, Democratis J (2008) The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 21: 626-638.
21. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417-427.